Topic
Non-Small Cell Lung Cancer (NSCLC)
9 Podcasts • 6 Cases • 2 Courses on BackTable
Hear how experienced physicians manage Non-Small Cell Lung Cancer (NSCLC) on BackTable. Learn from podcasts, cases, and courses curated by physician content creators, covering diagnosis, clinical decision-making, and treatments. Get the BackTable app to follow this Topic and hear more of the conversations that matter to your practice.
Episode # 47 • 10 Feb 2026
NSCLC Treatment: Bispecific Antibodies & EGFR Mutations
with Dr. Wade Iams, Dr. Kate Baker
Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do they work, where do they fit in clinical practice, and what should oncologists be thinking about next? In this episode of Back Table Tumor Board, Dr. Kate Baker and Dr. Wade Iams from Tennessee Oncology answer these questions and more.
More on Non-Small Cell Lung Cancer (NSCLC)
Loading recent podcasts…
Tumor Board Episode #47
Feb 10, 2026
with Dr. Wade Iams, Dr. Kate Baker
Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do...
300+ listens
Tumor Board Episode #40
Dec 16, 2025
with Dr. Venkatesh Krishnasamy, Dr. Scott Atay, Dr. Scott Genshaft, Dr. Scott Oh
Is the open thoracotomy becoming outdated as robotic surgery and advanced ablation techniques take center stage in lung...
1,100+ listens
VI Episode #591
Nov 21, 2025
with Dr. Scott Atay, Dr. Karen Reckamp, Dr. Alan Lee, Dr. Scott Oh, Dr. Scott Genshaft
When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first?...
1,200+ listens
VI Episode #589
Nov 14, 2025
with Dr. Scott Genshaft, Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh, Dr. Alan Lee
As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking...
1,700+ listens
VI Episode #605
Jan 9, 2026
with Dr. Venkatesh Krishnasamy, Dr. Scott Atay, Dr. Scott Genshaft, Dr. Scott Oh
Is the open thoracotomy becoming outdated as robotic surgery and advanced ablation techniques take center stage in lung...
1,100+ listens
VI Episode #595
Dec 5, 2025
with Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Genshaft, Dr. Venkatesh Krishnasamy
How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung...
1,400+ listens
Tumor Board Episode #36
Nov 18, 2025
with Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Genshaft, Dr. Venkatesh Krishnasamy
How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung...
1,400+ listens
Tumor Board Episode #35
Nov 14, 2025
with Dr. Scott Atay, Dr. Karen Reckamp, Dr. Alan Lee, Dr. Scott Oh, Dr. Scott Genshaft
When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first?...
1,200+ listens
VI Case
Nov 21, 2025
with Dr. Scott Genshaft, Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh and Dr. Alan Lee
VI Case
Nov 21, 2025
with Dr. Venkatesh Krishnasamy, Dr. Scott Atay, Dr. Scott Genshaft and Dr. Scott Oh
Tumor Board Case
Nov 11, 2025
with Dr. Venkatesh Krishnasamy, Dr. Scott Atay, Dr. Scott Genshaft and Dr. Scott Oh
VI Case
Nov 21, 2025
with Dr. Venkatesh Krishnasamy, Dr. Scott Atay, Dr. Scott Genshaft and Dr. Scott Oh
Tumor Board Case
Nov 11, 2025
with Dr. Venkatesh Krishnasamy, Dr. Scott Atay, Dr. Scott Genshaft and Dr. Scott Oh
Tumor Board Case
Nov 11, 2025
with Dr. Scott Genshaft, Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh and Dr. Alan Lee
Tumor Board Course
2 CME/CE credits, 2.5 hours, 26 lessons
Tumor Board Course
2 CME/CE credits, 2.5 hours, 19 lessons
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.